Vyome Holdings, Inc
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
1001 CALLE AMANECER, SAN CLEMENTE, CA, 92673
Mailing Address
1001 CALLE AMANECER, SAN CLEMENTE, CA, 92673
Phone
949-429-6680
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
-$1.45M
Net Income
$-4.86
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| DEF 14A Definitive proxy statement | March 31, 2026 | View on SEC |
| 10-K Annual financial report | March 18, 2026 | View on SEC |
| 8-K Current report of material events | February 25, 2026 | View on SEC |
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| 8-K Current report of material events | January 28, 2026 | View on SEC |
| 8-K Current report of material events | December 23, 2025 | View on SEC |
| 8-K Current report of material events | November 19, 2025 | View on SEC |
| 3 Initial insider ownership report | November 19, 2025 | View on SEC |
| 4 Insider stock transaction report | November 19, 2025 | View on SEC |
| 4 Insider stock transaction report | November 18, 2025 | View on SEC |
Annual Reports
10-K
March 18, 2026
- Successfully completed a reverse merger on August 15, 2025, making Vyome Holdings, Inc. a publicly traded entity.
- Advancing clinical pipeline with VT-1953 progressing to Phase 3 and VT-1908 initiating human trials by H2 2025.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.